Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Allogene Therapeutics
National Institutes of Health Clinical Center (CC)
Stanford University
Massachusetts General Hospital
University of California, San Francisco
Chinese PLA General Hospital
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
University of Chicago
Ossium Health, Inc.
M.D. Anderson Cancer Center
Hackensack Meridian Health